Merck and its subsidiary Organon announced a $100 million aggregate settlement of about 1,850 NuvaRing blood clot lawsuits and additional claims that might bring the total number of claimants to nearly 4,000. At least three studies found that NuvaRing birth control devices increased the risk of heart-related side effects, blood clots, and strokes.
NuvaRing is a flexible plastic (ethylene-vinyl acetate copolymer) ring that a woman can insert into her vagina as a birth control device. Over a three-week time period, it releases low doses of progestin and estrogen hormones.
NuvaRing risks are primarily cardiac in nature; they include the following:
- blood clots;
- myocardial infarction;
- pulmonary embolism (PE);
- deep vein thrombosis (DVT);
- heart attack;
- heart arrhythmia;
- gallbladder disease requiring surgery or removal of the gallbladder; and
NuvaRing’s adverse side effects are similar to those caused by traditional combined oral contraceptives, and they can be exacerbated by smoking and history of heart problems.
Studies Show Increased Risk of Blood Clots
Women’s bodies metabolize NuvaRing’s etonogestrel into desogestrel hormones, which increases the risk of blood clots by 1.5 to 2.4 times the risk of older oral contraceptives according to two studies published in the New England Journal of Medicine.
Additionally, in May 2012, the British Medical Journal published a meta-analysis of women who were using non-oral hormonal contraceptives (including NuvaRing) based on data contained in four Danish medical registries. The studies focused on 626,158 non-pregnant women between the ages of 15 and 49 who did not have a history of thrombosis or cancer between 2001 and 2010. The researchers determined that vaginal-ring use increased the risk of thrombosis by 6.5 times compared to women of the same age who did not use them. The risk corresponded to 7.8 thrombosis events per 10,000 exposure years.
NuvaRing Victims Are Receiving Settlement Compensation Offers
People believe Organon misled consumers by minimizing NuvaRing’s warnings on the product’s labeling. Nearly 2,000 have sued Organon and Merck in federal and state courts. A multidistrict litigation was formed in the U.S. District Court for the Eastern District of Missouri before Judge Rodney Sippel, and many other lawsuits are pending in New Jersey state-court multicounty litigation.
In early February 2014, Judge Sippel endorsed a $100 million aggregate NuvaRing settlement. Unlike similar settlements in other product liability mass actions, the settlement agreement does not specify the base award a claimant can obtain from a NuvaRing settlement. Like other settlements, though, the severity of a claimant’s injuries will influence her compensation.
How Can a Lawsuit Help Me?
If you or a loved one used NuvaRing and you believe it caused a blood clot injury, a lawsuit against Organon and Merck can help you obtain compensation for the harm you suffered. Even if you are interested in joining the mass settlement, you should talk to a NuvaRing lawyer from the Rottenstein Law Group to help maximize your settlement payment. The amount of compensation from a NuvaRing settlement or lawsuit can include damages for full medical expenses, lost earnings, pain and suffering, and other damages. For a free, confidential legal consultation with a lawyer from the Rottenstein Law Group, click on this link or call 1 (888) 976-8529. Inaction will not result in compensation and your time to act might be limited!